Lupus
Anti-Ro antibodies in lupus portend higher disease activity, steroid use
Patients with systemic lupus erythematosus who are positive for anti-Ro60 or anti-Ro52 antibodies may face higher disease activity and more intensive treatment needs, according to data published in Rheumatology.
New organ damage more common in lupus’ early stages; musculoskeletal system most impacted
Most new organ damage in systemic lupus erythematosus occurs in the first year after diagnosis, with the greatest impacts reported in the cardiovascular and musculoskeletal systems, according to data published in Lupus Science & Medicine.
Shared decision-making boosts trust in physicians among patients with lupus
Practicing shared decision-making increases overall trust in health care providers among patients with systemic lupus erythematosus, according to data published in Arthritis Care & Research.
FDA fast tracks CAR T-cell therapy for refractory lupus in anticipation of phase 1 trial
The FDA has granted fast track designation to CB-010, an allogeneic anti-CD19 CAR T-cell therapy from Caribou Biosciences, for refractory systemic lupus erythematosus ahead of a planned phase 1 trial, according to a press release.
Genetics, long-term air pollutant exposure combine to increase lupus risk
Long-term exposure to air pollutants, including particulate matter, increases the risk for developing systemic lupus erythematosus, according to data published in Arthritis & Rheumatology.
‘A large overlap’: Autoimmune encephalitis can look like, coexist with rheumatic disease
ORLANDO, Fla. — Although rheumatic diseases must be considered in a differential diagnosis of autoimmune encephalitis, some patients can have both, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.
‘Pristine’ safety profile sets TYK2i apart from JAK ‘baggage’ in psoriatic disease, lupus
In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.
Infections account for majority of in-hospital deaths in childhood lupus
Infections account for most in-hospital mortality in childhood systemic lupus erythematosus, with patients exhibiting lupus nephritis or end-stage renal disease at increased risk, according to data published in The Journal of Rheumatology.
Renal, cardiovascular risks lower in patients with lupus using metformin
Metformin may protect against the progression of adverse renal and cardiovascular outcomes in patients systemic lupus erythematosus, including lupus nephritis and infarction, according to data published in ACR Open Rheumatology.
IFN signature in lupus endotypes may lead to ‘targeted and personalized’ treatments
Specific interferon signatures may influence the symptoms and severity of systemic lupus erythematosus, with various interferon types potentially “contributing to distinct pathogenic processes,” according to recent findings.